echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA: Cancer risk after radioactive iodine treatment of hyperthyroidism

    JAMA: Cancer risk after radioactive iodine treatment of hyperthyroidism

    • Last Update: 2021-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Importance: Whether radioactive iodine (RAI) treatment of hyperthyroidism (hyperthyroidism) will increase the risk of cancer is still a controversial issue in the fields of medicine and public health
    .

    Whether radioactive iodine (RAI) treatment of hyperthyroidism (hyperthyroidism) will increase the risk of cancer is still a controversial issue in the fields of medicine and public health
    .

    OBJECTIVE: To study the incidence and mortality of cancer in a specific site after RAI treatment for hyperthyroidism (hyperthyroidism), and to evaluate the radiation dose-response relationship


    .


    Data source: Medline and Cochrane library electronic databases, using medical subject terms and text keywords, Embase, using Emtree, filtering until October 2020
    .

    Study selection: The inclusion criteria are as follows: (1) Include patients with hyperthyroidism receiving RAI treatment and follow-up until cancer diagnosis or death; (2) Include at least 1 individual who has not received RAI treatment (for example, the general population or undergoing thyroidectomy or Patients with hyperthyroidism treated with antithyroid drugs) or a control group consisting of patients with hyperthyroidism treated with different doses of RAI; (3) The effect size measurement standards (ie standardized morbidity rate [SIR], standardized mortality rate [SMR], hazard ratio [HR] ]), and (3) include effect size measurement (i.
    e.
    standardized incidence rate [SIR], standardized mortality [SMR], hazard ratio [HR]), and (3) include effect size measurement (i.
    e.
    standardized incidence rate [SIR] , Standardized Mortality [SMR], [HR])
    .

    Data extraction and analysis: Two independent researchers extracted data according to the Meta-analysis (MOOSE) guidelines for epidemiological observational studies
    .
    The comprehensive quality assessment followed the recommendations of the United Nations Scientific Committee on the Effects of Atomic Radiation


    .


    Main results and measures: The incidence and mortality of cancers exposed to and without RAI treatment, and the level of RAI treatment activity
    .

    Results: Based on data from 12 studies (including 479,452 participants), the overall cancer combined incidence rate ratio between exposure to RAI treatment and non-exposure to RAI treatment was 1.
    02 (95% CI, 0.
    95-1.
    09), and the combined cancer mortality ratio It is 0.
    98 (95% CI, 0.
    92-1.
    04)
    .
    Except for the incidence of thyroid cancer (SIR, 1.


    86; 95% CI, 1.


    Table 1 Meta-analysis of cancer risk incidence and mortality after radioactive iodine treatment of hyperthyroidism

    Table 1 Meta-analysis of cancer risk incidence and mortality after radioactive iodine treatment of hyperthyroidism

    Table 2 The relationship between regulatory factors and overall cancer risk after radioactive iodine therapy in hyperthyroidism

    Table 2 The relationship between regulatory factors and overall cancer risk after radioactive iodine therapy in hyperthyroidism

    Figure Dose-effect relationship of linear and non-linear models of radioactive iodine dose and cancer mortality

    Figure Dose-effect relationship of linear and non-linear models of radioactive iodine dose and cancer mortality

    Conclusions and correlation: In this meta-analysis, there was no significant difference in overall cancer risk between RAI treatment and no exposure, but there was a linear dose-response correlation between RAI treatment and solid cancer mortality
    .
    These findings indicate that the risk of radiation-induced cancer after RAI treatment of hyperthyroidism is small, and in observational studies, it may only be detected at higher doses


    .


    In this meta-analysis, there was no significant difference in the overall cancer risk between RAI treatment and no exposure, but there was a linear dose-response correlation between RAI treatment and solid cancer mortality


    Shim SR, Kitahara CM, Cha ES,et al.


    Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.


    Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.
    JAMA is here to leave a message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.